{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:31:28Z","timestamp":1780579888376,"version":"3.54.1"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia from teaching and research subsidy funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Ofatumumab (OFA) is the first fully human anti-CD20 monoclonal antibody approved for the treatment of RRMS classified as a high-efficacy treatment agent. Real-world evidence is essential for evaluating the effectiveness and safety of OFA. Materials and Methods: A total of 184 patients (72.3% women, mean age 38 years (\u00b110.9), 51 na\u00efve patients and 133 after switch. Among them, 142 patients were evaluated after first 12-months of treatment according to relapse rate, neurological status expressed by Expanded Disability Status Scale (EDSS), new T2-weighted (T2-w) lesions and gadolinium-enhancing lesions (GELs) in magnetic resonance imaging (MRI), confirmed disability progression, as well as adverse events. Logistic regression identified factors associated with disease activity at ofatumumab initiation, including age, sex, disease duration, prior treatment, and baseline EDSS. Results: After the first 12 months of OFA treatment, relapses occurred in 12.0% of patients; new or enlarging T2-w lesions were observed in 12.7%; GELs in 3.5%; EDSS progression in 12.7%; and EDSS improvement in 14.2%. The No Evidence of Disease Activity-3 (NEDA-3) status was achieved in 76.1% of patients overall\u201475.8% in those who switched from another disease-modifying therapy (DMT), and 76.6% in treatment-na\u00efve individuals. No significant differences were observed between the na\u00efve and switch groups. Baseline EDSS at ofatumumab initiation was a significant predictor of relapse activity, while age was significantly associated with MRI activity (GELs) at 12 months. Conclusions: Real-world data confirmed high efficacy and safety of ofatumumab in RRMS. NEDA-3 was achieved more often than in registration trials. No efficacy differences between na\u00efve and switch patients were observed.<\/jats:p>","DOI":"10.3390\/medicina61091568","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:28:15Z","timestamp":1756715295000},"page":"1568","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Data of First 12-Months of Ofatumumab Treatment in Multiple Sclerosis Patients\u2014A Multicenter Experience from Tertiary Referral Centers"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-7013","authenticated-orcid":false,"given":"Weronika","family":"Galus","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kaczmarczyk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Walawska-Hrycek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-660X","authenticated-orcid":false,"given":"Joanna","family":"Siuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Polewka","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association, Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Lasek-Bal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-5660","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Puz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_2","first-page":"20","article-title":"Epidemiology of multiple sclerosis: Global trends, regional differences, and clinical implications","volume":"59","author":"Kulakowska","year":"2025","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuroscience.2024.12.029","article-title":"A review on multiple sclerosis: Unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations","volume":"567","author":"Zainab","year":"2025","journal-title":"Neuroscience"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: A review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1107-e101","DOI":"10.1111\/ene.13669","article-title":"\u2018No evidence of disease activity\u2019\u2014is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_7","first-page":"2055217321999070","article-title":"Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis","volume":"7","author":"Healy","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_8","first-page":"4130557","article-title":"Brain atrophy as an outcome of disease-modifying therapy for remitting-relapsing multiple sclerosis","volume":"2023","author":"Wyszomirski","year":"2023","journal-title":"Mult. Scler. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"a032037","DOI":"10.1101\/cshperspect.a032037","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/TCRM.S282390","article-title":"Ocrelizumab for the treatment of multiple sclerosis: Safety, efficacy, and pharmacology","volume":"17","author":"Mancinelli","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase 2 study","volume":"28","author":"Wiendl","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study","volume":"82","author":"Sorensen","year":"2014","journal-title":"Neurology"},{"key":"ref_16","first-page":"e1805","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Grove","year":"2018","journal-title":"Neurology"},{"key":"ref_17","unstructured":"Novartis Pharma, A.G. (2025, May 15). Kesimpta\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf."},{"key":"ref_18","first-page":"118","article-title":"Dose-dependent tolerability of intravenous and subcutaneous ofatumumab in clinical studies","volume":"26","author":"Mairon","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_19","unstructured":"Ministerstwo Zdrowia (2025, May 15). Programy Lekowe, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/programy-lekowe."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5603\/PJNNS.a2020.0084","article-title":"Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis","volume":"54","author":"Hartel","year":"2020","journal-title":"Neurol. I Neurochir. Pol."},{"key":"ref_23","unstructured":"National Cancer Institute (2025, August 22). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hauser, S.L., Cohen, J.A., de S\u00e8ze, J., Meuth, S.G., Giacomini, P.S., Nakahara, J., Oreja-Guevara, C., Robertson, D., Wray, S., and Bhatt, A. (Neurol. Ther., 2025). Five-year efficacy safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis, Neurol. Ther.","DOI":"10.1007\/s40120-025-00784-0"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17582024.2025.2452150","article-title":"Real-world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice","volume":"15","author":"Amin","year":"2025","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1007\/s00415-024-12581-0","article-title":"Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study","volume":"271","author":"Karl","year":"2024","journal-title":"J. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"St\u0119pie\u0144, A., Pogoda-Weso\u0142owska, A., Staszewski, J., Brola, W., Kania, K., Krzystanek, E., Rusek, S., Zajdel, R., Ha\u0142as, M., and Karaszewski, B. (Arch. Med. Sci., 2025). Early Treatment with Ofatumumab Increases the Likelihood of Stabilizing Disease in Patients with Relapsing-Remitting Multiple Sclerosis, Arch. Med. Sci.","DOI":"10.5114\/aoms\/205112"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106617","DOI":"10.1016\/j.msard.2025.106617","article-title":"Real-World Change in Annualized Relapse Rate and Healthcare Resource Utilization Following Initiation of Ofatumumab in People with Multiple Sclerosis","volume":"102","author":"Tai","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","article-title":"Ocrelizumab and Ofatumumab Comparison: An Italian Real-World Propensity Score Matched Study","volume":"271","author":"Borriello","year":"2024","journal-title":"J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1212\/WNL.0000000000202906","article-title":"Five-Year Safety of Ofatumumab in People Living with Relapsing Multiple Sclerosis (P8-3.004)","volume":"100","author":"Cohen","year":"2023","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Wu, Y., Zhao, X., Xu, L., Sun, M., and Meng, Z. (2025). The real-world safety of ofatumumab: A pharmacovigilance analysis based on the FDA adverse event reporting system. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1515730"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chen, H. (2025). Real-World Pharmacovigilance of Ofatumumab in Multiple Sclerosis: A Comprehensive FAERS Data Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1521726"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105888","DOI":"10.1016\/j.msard.2024.105888","article-title":"Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis","volume":"91","author":"Hersh","year":"2024","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:36:24Z","timestamp":1760034984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091568"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091568","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}